Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD).
• These conditions impact the endothelium, activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways.
• Severity and duration of risk factors contribute to cardiovascular risk via oxidative stress and inflammation.

Purpose of the Study:

• To review the influence of hypertension and hypercholesterolemia on cardiovascular risk.
• To examine the clinical evidence for statins and ACE inhibitors in managing ASCVD.
• To highlight the combined benefits of these drug classes.

Main Methods:

• Literature review of clinical evidence.
• Analysis of studies on statins and ACE inhibitors.
• Examination of drug strategies for ASCVD management.

Main Results:

• Statins and ACE inhibitors show benefits individually and combined for hypertension, lipid disorders, and ASCVD.
• Combined therapy, particularly perindopril and atorvastatin, reduces ASCVD events.
• These drugs are established as first-line therapies.

Conclusions:

• Combined ACE inhibitor and statin therapy is effective for managing atherosclerosis complications.
• Perindopril and atorvastatin demonstrate significant reductions in ASCVD events.
• These drug strategies are crucial for patients with hypertension and lipid disorders.